Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × MEK inhibitor I × Dermatologic × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 50 Cyclophosphamide 48 Ipilimumab 42 Nivolumab 37 aldesleukin 31 Interleukin-2 22 fludarabine 21 fludarabine phosphate 20 Vemurafenib 19 Radiotherapy 17 Temozolomide 16 dabrafenib 15 trametinib 12 Radiosurgery 10 Filgrastim 9 Dacarbazine 9 Biopsy 9 spartalizumab 8 cobimetinib 8 binimetinib 8 Antilymphocyte Serum 8 poly ICLC 7 Introns 7 CTLA-4 Antigen 7 encorafenib 6 atezolizumab 6 Rituximab 6 Peripheral Blood Stem Cell Transplantation 6 Mycophenolic Acid 6 Cyclosporine 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02382549 2023-12-12

Mel61

University of Virginia

Phase EARLY_PHASE1 Terminated

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡